8:30 ‐ 8:40 AM	Opening Remarks and Introduction
8:40 - 9:00 AM	The Personalized Medicine Landscape Clarissa Desjardins, CEPMED
9:00 - 9:20 AM	Rewards and Risks of Using Biomarkers in Drug Development Agnes Klein, Health Canada
9:20 - 9:40 AM	CIHR Initiatives - Advancing Research and Practice Peter Liu, CIHR/ U Toronto
9:40 - 10:00 AM	Imaging as a fine phenotyping modality to validate biomarkers J-C Tardif, Montreal Heart
10:00 - 10:20 AM	BREAK
10:20 - 10:40 AM	GWAS and sequencing studies John Rioux, Montreal Heart Institute
10:40 - 11:00 AM	Pharmacogenomics Michael Phillips, Montreal Heart Institute
11:00 - 12:00 PM	PANEL DISCUSSION
12:00 - 1: 00 PM	LUNCH BREAK
1:00 - 1:20 PM	Novel Approaches and Clinical Utility Peter Libby, Harvard Medical School
1:20 - 1:40 PM	Clopidogrel and genetic variance Jessica Mega, Brigham and Women's Hospital
1:40 - 2:00 PM	Hepatic Safety Brian Foster, Health Canada
2:00 - 2:20 PM	Molecular Imaging and Personalized Medicine Donald Black, CMOD
2:20 - 2:40 PM	BREAK
2:40 - 3:40 PM	Case Studies: Pharma /Diagnostic
3:40 - 4:00 PM	Public Policy Narayanan Iyer, Health Canada
4:00 - 5:00 PM	Panel Discussion How can Canada lead in the adoption of personalized medicine strategies?
5:00	Conclusion and Adjourn

Patrice Hugo
Robert Wasserman
Helen Wu